<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592084</url>
  </required_header>
  <id_info>
    <org_study_id>IRB(2)0609-0087</org_study_id>
    <nct_id>NCT01592084</nct_id>
  </id_info>
  <brief_title>Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Cohort Study of the Relationship of Hyperlipidemia and Statin Therapy on Survival and Disease Progresssion in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis
      (ALS) pathophysiology and its impact on disease progression and survival is unclear. The
      investigators analyzed the correlation between lipid levels with disease progression and
      survival in ALS patients and the association of LLT with these outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>survial(tracheostomy free,&lt;23 hours on NIPPV, from enrollment)</measure>
    <time_frame>3years</time_frame>
    <description>Death was confirmed from Social Security Death Index or newspaper obituaries. Tracheostomy- ventilation was also considered as an end of the life time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALSFRS(measure of disability)</measure>
    <time_frame>at first evaluation(time 0-T0) to six months (T6)</time_frame>
    <description>DeltaFS = (48-ALSFRS at first evaluation )/duration from onset to diagnosis (month) changeFS=(ALSFRS at six months-ALSFRS at first evaluation)/6</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">267</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>lipid lowering therapy</arm_group_label>
    <description>those with lipid lowering therapy those without lipid lowering therapy</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        the Methodist Neurological Institute
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of laboratory-supported probable, probable, or definite familial,
             sporadic ALS, according to a modified El Escorial criteria (ref), by the study
             investigators

          -  Time from disease onset is less than three years

               -  18 years of age

          -  Subjects with diagnosis of hyperlipidemia and/or taking lipid lowering medications
             will not be excluded from study.

        Exclusion Criteria:

          -  Requirement for tracheotomy ventilation or non-invasive ventilation for &gt; 23 hours per
             day

          -  Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease,
             etc)

          -  A clinically significant history of significant medical illness (advanced cancer,
             chronic inflammatory/infectious conditions, etc) within six months of baseline

          -  Use of progestins, anabolic steroids, and corticosteroids within 45 days of baseline
             visit. Therapy is allowed as medically indicated after baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ericka P Simpson, M.D</last_name>
    <role>Study Director</role>
    <affiliation>the Methodist Neurological Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <last_update_submitted>May 3, 2012</last_update_submitted>
  <last_update_submitted_qc>May 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital System</investigator_affiliation>
    <investigator_full_name>Sharon Halton</investigator_full_name>
    <investigator_title>Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>lipid lowering therapy</keyword>
  <keyword>survival</keyword>
  <keyword>ALSFRS</keyword>
  <keyword>age</keyword>
  <keyword>BMI</keyword>
  <keyword>weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 22, 2012</submitted>
    <returned>November 23, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

